Autori: Cho BC
| Naslov | Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC (Meeting Abstract) |
| Autori | Cho BC ... Secen Nevena M ... (broj koautora 19) |
| Info | ANNALS OF ONCOLOGY, (2021), vol. 32 br. , Suppl. 7, str. S1428-S1428 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
